Mutation News and Research

RSS

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

FunMap reveals new insights into cancer-associated genes and proteins

Large-scale protein and gene profiling have massively expanded the landscape of cancer-associated proteins and gene mutations, but it has been difficult to discern whether they play an active role in the disease or are innocent bystanders.

11 Dec 2024

New research explores hidden health risks of hereditary hemochromatosis

A study links undetected diabetes in hemochromatosis patients to increased mortality, highlighting the need for early detection and revised clinical guidelines.

11 Dec 2024

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of high-grade serous ovarian cancer (HGSOC). By assessing metabolic activity, it also identifies early and variable responses to chemotherapy, improving precision in treatment strategies.

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

New advances offer hope for patients with systemic mastocytosis

Dana-Farber Cancer Institute researchers are breaking new ground in the fight against systemic mastocytosis, a rare and heterogeneous condition that is often challenging for clinicians to accurately diagnose and treat.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Study identifies potential risk factor for aortic aneurysms in Loeys-Dietz syndrome

Studying the cells of people and genetically engineered mice, Johns Hopkins Medicine scientists say they have uncovered a potential reason why patients with Loeys-Dietz syndrome, an inherited connective tissue disorder, are especially prone to developing aneurysms at the root of the aorta, the major artery that carries blood away from the heart and to the rest of the body.

9 Dec 2024

Pioneering study discovers new genetic links to pancreatic cancer in Brazil

Pancreatic cancer has recently been included in the list of diseases about which Brazil's National Cancer Institute (INCA) periodically publishes statistics.

9 Dec 2024

Single mutation in (HPAI) H5N1 influenza virus could increase human transmission risk

A single modification in the protein found on the surface of the highly pathogenic avian influenza (HPAI) H5N1 influenza virus currently circulating in U.S. dairy cows could allow for easier transmission among humans, according to new research funded by the National Institutes of Health (NIH) and published today in the journal Science.

9 Dec 2024

Bovine H5N1 influenza shows potential for human adaptation through key mutations

Recent study reveals H5N1 mutations enhancing human receptor binding, highlighting pandemic risks and the need for vigilant surveillance of influenza strains.

9 Dec 2024

p53 mutations show diverse impact on pancreatic cancer metabolism

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas.

6 Dec 2024

Scientists identify molecular mechanism behind idiopathic autism

Autism is a neurodevelopmental disorder characterized by difficulties in communication and social behavior. Approximately 20% of cases are linked to a specific genetic mutation, but the origin of the remaining 80%, known as idiopathic autism, remains a mystery.

4 Dec 2024

Novel single-cell genomics analysis approach provides direct insights into cell cycle and proliferation

By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies key clones in cancer progression.

4 Dec 2024

SRF awards $230,000 grant to advance research on SYNGAP1-Related Disorders

The SynGAP Research Fund (SRF) has awarded a $230,000 grant to The Jackson Laboratory Rare Disease Translational Center to characterize a mouse model for SYNGAP1-Related Disorders, (SRD), a severe neurodevelopmental disorder marked by seizures, intellectual disabilities, and motor and behavioral challenges.

4 Dec 2024

Behavioral chaos in Alzheimer’s disease mice decoded by machine learning

Researchers use machine learning to identify behavioral disruptions in Alzheimer’s disease mouse models, highlighting a potential therapeutic target in fibrinogen-microglia interactions.

3 Dec 2024

Research sheds light on how mutated PSEN2 accelerates familial Alzheimer's disease progression

Alzheimer's disease is a debilitating condition that slowly robs people of their memory and cognitive abilities, affecting millions of people worldwide.

3 Dec 2024

Beta-blocker drugs may slow Huntington's disease progression

A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers.

2 Dec 2024

Study reveals protein mobility defect as a key factor in chronic diseases

Chronic diseases like type 2 diabetes and inflammatory disorders have a huge impact on humanity. They are a leading cause of disease burden and deaths around the globe, are physically and economically taxing, and the number of people with such diseases is growing.

27 Nov 2024